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The surgical management of colorectal liver metastases (CLM)
has evolved over recent decades to bring radical treatment and
potential cure within the reach of many more patients. Successful
strategies include parenchyma-sparing segmental resection, com-
bined resection and ablation, staged resection, portal vein embo-
lization, repeat hepatectomy, resection of limited extrahepatic
disease, and systemic therapy to downstage initially inoperable
disease. Advances in cross-sectional imaging, such as multi-
detector computed tomography (CT) and magnetic resonance
imaging (MRI), and nuclear medicine 18F-fluorodeoxyglucose
positron emission tomography (FDG-PET) have also
improved preoperative staging, with the result that the ‘open and
close’ laparotomy has, fortunately, become rare. Together, these
advances have led to improvements in longterm survival, despite
extending the limits of radical treatment.1,2
In this issue of the journal, Knowles et al. examine the question
of baseline imaging in patients referred for resection of CLM. The
authors conclude that liver-specific MRI, performed prior to neo-
adjuvant chemotherapy, leads to better patient outcomes by
reducing intrahepatic recurrence and the need for repeat hepate-
ctomy. A crucial point of difference in this study is that it applies
important clinical endpoints rather than merely comparing sen-
sitivity and specificity rates.
The study utilized a prospectively maintained database to iden-
tify 242 patients who had undergone neoadjuvant chemotherapy
followed by liver resection in a single institution and divided them
into those who had undergone baseline imaging with liver-specific
MRI and those who had undergone CT, non-contrast MRI or
gadolinium-enhanced MRI. Liver-specific MRI utilizes contrast
agents that are taken up by normal hepatocytes and therefore
accentuates the contrast differential between CLM and surround-
ing hepatic parenchyma during dynamic sequences. All patients
underwent liver-specific MRI between neoadjuvant chemo-
therapy and surgery. FDG-PET scans were not routinely per-
formed. The most important finding was that patients who did
not undergo liver-specific MRI at baseline showed more intrahe-
patic recurrences (this increase was statistically significant when
resection margin recurrences were excluded). These patients
required more repeat hepatectomies to achieve longterm survival
equivalent to that in the group in which baseline imaging with
liver-specific MRI had been performed. The implication is that
liver-specific MRI detected more lesions at baseline, particularly
small lesions that are inclined to ‘disappear’ in response to che-
motherapy. If these ‘disappearing’ lesions had been identified
prior to chemotherapy, it is more likely they would have been
encompassed within the planned resection. Another important
finding was that liver-specific MRI prior to chemotherapy led to a
change in tumour staging in more than half of all patients, and in
nine patients one or more suspected liver lesions were benign.Any
surgeon who has carried out an unnecessary liver resection for a
sclerosed haemangioma or benign bile duct adenoma, believing it
to be a CLM, will appreciate the value of fully characterizing
lesions preoperatively.
If the findings of this study are robust, it will set a new standard
in the workup of patients with resectable CLM.We should there-
fore look critically at methodological aspects of the study. The
investigators had at their disposal a large, prospectively main-
tained database with good longterm follow-up, but the study is
essentially a post hoc analysis of a selected subset of patients (242
of 715) drawn from the database. The patients were not prospec-
tively selected and not randomized and unmeasured differences
between the groups may have existed and may have influenced the
choice of both baseline imaging and outcome measures. Of 419
patients who underwent neoadjuvant chemotherapy, 155 were
excluded because they received ‘suboptimal’ chemotherapy,
defined as fewer than three cycles of oxaplatin or irinotecan-based
treatment, or fluorouracil and leucovorin (FU/LV) alone.
However, irinotecan has no additional benefit over FU/LV alone in
the adjuvant setting, for either primary or metastatic colorectal
cancer,3,4 so there would appear to be no good rationale for
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selecting on this basis. It would have been more rigorous to
include all patients going forward for neoadjuvant therapy, thus
emulating an intent-to-treat analysis, or to include only those
treated by a regimen reflecting the current standard of care, which
does not include irinotecan. Finally the primary endpoint of
intrahepatic recurrence was only significant when resection
margin recurrences were excluded. However, this may be reason-
able given that positive margin resections (15% and 13%, respec-
tively) and margin recurrence rates (30% and 23%, respectively)
were similar in both groups, which lends support to the hypoth-
esis that lesions elsewhere in the liver that were missed on imaging
explain the higher recurrence rate in patients who did not
undergo baseline imaging with liver-specific MRI.
Three months of chemotherapy before and after liver resection
has become the standard of care for resectable CLM based on the
European Organization for Research and Treatment of Cancer
(EORTC) study 409835. The study by Knowles et al. raises another
very important issue, which is the management of lesions that
‘disappear’ during neoadjuvant chemotherapy.We now know that
the correlation between radiological disappearance and complete
pathological response is poor and that 80% of such lesions are
likely to recur within 12 months if they are left untreated.6 Indeed,
this is part of the rationale for the ATTACHE trial, an Australasian
Gastrointestinal Trials Group-sponsored study comparing pre-
and postoperative adjuvant chemotherapy with postoperative
chemotherapy for resectable CLM. As well as reducing lesion size,
chemotherapy promotes hepatic steatosis (limiting the sensitivity
of CT) and reduces tumour metabolic activity (limiting the sen-
sitivity of FDG-PET), and thus MRI is likely to be superior in this
setting.7 Unlike the present study, another prospective study failed
to demonstrate the superiority of liver-specific MRI over
gadolinium-enhanced MRI for detection of CLM.8
So where does this leave us? It would be easy to say that the
findings of Knowles et al. need to be validated by a well-designed
prospective study, but this is unrealistic because the minimum
period needed to recruit participants and reach clinical endpoints
is 5–10 years. During that time, imaging technology will inevitably
move forward. By contrast, there is little disadvantage to recom-
mending liver-specific MRI for staging the liver in CLM.
Gadolinium-ehhanced MRI has been shown to have advantages
over CT in this context7 and the report by Knowles et al. strongly
suggests, although does not prove, that liver-specific MRI is better
still. There are no additional patient risks and the marginal cost
of liver-specific contrast is minute compared with the overall
treatment cost of combined chemotherapy and surgery. The
avoidance of even a few repeat hepatectomies and unnecessary
hepatectomies for benign disease will reduce both cost and patient
morbidity. A greater logistic challenge is to educate surgical and
oncological colleagues to refer patients prior to the commence-
ment of neoadjuvant chemotherapy so that thorough baseline
assessment, including liver-specific MRI for the liver and PET-CT
for extrahepatic disease, is ensured. It may also be that selected
patients are better served with surgery prior to chemotherapy,
although we must await the results of the ATTACHE trial to better
define the respective risks and benefits of peri- and postoperative
adjuvant chemotherapy for resectable CLM.
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